NeoGenomics (NEO) said Wednesday it expects 2025 total revenues in the range of $735 million to $745 million.
Analysts surveyed by FactSet expect $727.8 million.
NeoGenomics said, as part of its long-range financial plan, it intends to achieve 12-13% revenue growth annually and positive cash flow from operations in 2025 and beyond. The company also aims to serve over 1 million patients per year by 2028.
NeoGenomics shares were up almost 4% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。